Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553993 | 0.92 | CNR1 (0.46) | CNR1MAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL3559947 | 0.86 | CNR1 (0.42) | CNR1MAPTTP53SMN1; SMN2KDM4E | |
| SCHEMBL3566766 | 0.84 | CNR1 (0.48) | CNR1MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3559074 | 0.82 | CNR1 (0.46) | CNR1MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3564369 | 0.81 | CNR1 (0.48) | CNR1MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3565680 | 0.80 | CNR1 (0.48) | CNR1MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL3560700 | 0.79 | CCR5 (0.51) | CNR1MAPTTP53SMN1; SMN2KCNH2 | |
| SCHEMBL3563077 | 0.79 | CCR5 (0.54) | CNR1MAPTTP53SMN1; SMN2KCNH2 | |
| SCHEMBL3554924 | 0.79 | L3MBTL1 (0.51) | CNR1MAPTTP53SMN1; SMN2LMNA | |
| SCHEMBL302944 | 0.77 | CNR1 (0.46) | CNR1MAPTTP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CNR1 16/4885MAPT 1151/4885TP53 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.